跳至主要内容
临床试验/NCT03099798
NCT03099798已完成不适用

Traumatic Splenic Injury and Management (SPLENIQ Study) Quality of Life and Clinical Outcomes of Treatment for Splenic Injury After Trauma

Elisabeth-TweeSteden Ziekenhuis10 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2017年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
106
试验地点
10
主要终点
Quality of Life: baseline (within 1 week after treatment)

研究概览

简要总结

OBJECTIVE:

To determine the quality of life (QOL) and clinical outcome after conservative therapy, embolization (proximal versus distal) or surgery in patients with traumatic splenic injury. Secondary aims: (I) to examine therapy-related complications, (II) to establish the necessity of additional therapies, (III) the assessment of splenic function related to splenic morphology (MR imaging) after embolization and (IV) to find the prognostic factors for failure of non-operative management (NOM) in patients with splenic injuries. Finally, with the acquired data from this study a patient-oriented protocol will be provided for the management of traumatic splenic injury.

HYPOTHESIS:

The investigators expect that NOM is superior to surgery with regard to QOL, clinical outcome and splenic function. Embolization will need more additional therapies. Splenic morphology is related to splenic immune function. Expected prognostic factors are age above 40, ISS >25 and a splenic injury grade of 3 or higher.

STUDY DESIGN:

A combination of a retrospective and a prospective multicentre cohort study. This protocol involves the prospective part of the study.

STUDY POPULATION/DATASET:

Patients who enter the participating hospitals between March 2017 and December 2018 with splenic injury will be asked to participate. The follow-up period will be one year with regard to QOL, clinical symptoms and imaging.

INTERVENTION:

All patients will complete a number of questionnaires at different time points. The patients who were treated with splenic artery embolization (SAE) will undergo an MRI one month and one year after treatment.

OUTCOME MEASURES:

Primary outcome is QOL. Secondary outcomes are clinical symptoms and imaging.

SAMPLE SIZE:

Approximately 100 patients will be included per year during the inclusion phase.

DATA ANALYSIS:

With regard to the prospective data linear modelling will be performed.

COLLABORATION/CONNECTION:

Tilburg University, Erasmus Medical Center Rotterdam, Maasstad Hospital Rotterdam, Albert Schweitzer Hospital Dordrecht, Amphia hospital Breda, Leiden University Medical Center, VU University Medical Center Amsterdam, Medical Spectrum Twente, Radboud University Nijmegen, Isala Zwolle.

TIME SCHEDULE:

Year 1: literature search and conducting the retrospective study and analyses. Years 1-3: inclusion prospective study and follow-up of patients. Year 4: finishing follow-up data collection and analysing.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Splenic injury after blunt abdominal trauma (confirmed by FAST and/or CT)
  • The patient underwent NOM/SAE/splenectomy for the management of traumatic splenic injury
  • The treatment took place in the period from March 2017 to December 2018 at one of the five selected hospitals
  • 18 years or older.

排除标准

  • Insufficient knowledge of the Dutch language
  • Patients who died during or after treatment are (of course) excluded for questionnaires and MRI, not for clinical outcomes
  • Exclusion for MRI only:
  • Patients treated with SAE: patients who do not want to or are not able to undergo an MRI abdomen (for example pregnant women or other contraindications for MRI). Patients excluded for MRI still need to fill out the questionnaires. Also, their clinical outcomes will be processed in the database.

结局指标

主要结局

Quality of Life: baseline (within 1 week after treatment)

时间窗: One week after treatment

WHOQoL-Bref questionnaire, SF-12 and EQ-5D-5L questionnaires

Quality of life: 3 months follow-up

时间窗: Three months after treatment

WHOQoL-Bref questionnaire

Quality of life: 6 months follow-up

时间窗: Six months after treatment

WHOQoL-Bref questionnaire

Change in health status: SF-12

时间窗: One week, 1 month and 3, 6 and 12 months after treatment

SF-12 questionnaire

Quality of life: 1 month follow-up

时间窗: One month after treatment

WHOQoL-Bref questionnaire

Quality of life: one year follow-up

时间窗: One year after treatment

WHOQoL-Bref questionnaire

Change in health related quality of life: EQ-5D-5L

时间窗: One week, 1 month and 3, 6 and 12 months after treatment

EQ-5D-5L questionnaire

次要结局

  • Clinical Outcome(One year follow-up)
  • Imaging Outcome after Embolization (one month after treatment)(One month after embolization)
  • Imaging Outcome after Embolization (one year after treatment)(One year after embolization)
  • Splenic Artery Embolization characteristics(One year follow-up)
  • Cost-effectiveness(One year follow-up)
  • Prognostic factors for failure of Non-Operative Management(One year follow-up)

研究者

发起方
Elisabeth-TweeSteden Ziekenhuis
申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验